Search

Introduction: Primary hyperaldosteronism (PHA), is a clinical syndrome that is defined as inappropriately increased serum aldosterone secretion and low plasma renin levels. PHA has been reported as the most common cause of secondary hypertension. In this retrospective study, we planned to show the significance of screening for this disease in hypertensive patients admitted to our clinic. Methods: Our study included 64 patients who were admitted to our cardiology outpatient clinic between April 2018 and August 2021 with high blood pressure and were selected to be checked for plasma renin activity (PRA), PAC, and PAC/PRA ratios to exclude secondary hypertension. Medical records, hypertension treatments, and medical histories of the patients were reviewed from our hospital database. Results: Of the 64 patients, 25 (39.1%) were female and 39 (60.9%) were male. After the first evaluation of the patients, 13 patients were decided to be assessed with the saline infusion test. PHA was diagnosed in 7 of 13 patients evaluated. In the adrenal MRI performed in 3 of 7 patients diagnosed with PHA, one adrenal hyperplasia and one adrenal adenoma were diagnosed in 2 different patients. Conclusion: Primary hyperaldosteronism is one of the most important causes of secondary hypertension. Although there are various methods such as screening tests, the most commonly used method is the aldosterone/renin ratio and it is very practical to screen. Considering the various cardiovascular diseases that PHA is associated with, and the simplicity of treatment of PHA, we strongly believe that the screening threshold for PHA should be kept as low as possible and should be independent of age. [ABSTRACT FROM AUTHOR]

Introduction: Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome-coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic therapy before coronavirus disease-2019 (COVID-19) for any reason compared to the group who had not. Methods: In this retrospective, multicenter study; patients who were hospitalized between March 11 and July 1, 2020 were divided into two main groups as who had been on anti-thrombotic therapy for any indication use previously at the time of admission or who had not been on anti-thrombotic therapy at the time of admission, and their selected clinical parameters were compared. Results: After analyzing the study population of 124 patients with a homogeneous distribution in terms of age and gender, the comparison of anti-thrombotic users and non-users showed no significant difference in hospitalization. There was a statistically significant decrease in mechanical ventilation apply rate, intensive care unit duration and mortality rate between the group using anti-thrombotic compared to the group not using it (p<0.05). Conclusion: It has already been shown that COVID-19 patients are more prone to thromboembolic events as it activates the coagulation cascade with the cytokine storm it creates and thus the mortality of COVID-19 infection increases significantly. Parallel to this fact the results of our study demonstrated that using anti-thrombotic therapy for any reason may affect the bad prognosis of the disease positively. [ABSTRACT FROM AUTHOR]